miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer

被引:169
作者
Karaayvaz, M. [1 ]
Zhai, H. [1 ]
Ju, J. [1 ]
机构
[1] SUNY Stony Brook, Dept Pathol, Translat Res Lab, Stony Brook, NY 11794 USA
关键词
miR-129; BCL2; 5-fluorouracil; colorectal cancer; HEPATOCELLULAR-CARCINOMA; MULTIDRUG-RESISTANCE; THYMIDYLATE SYNTHASE; MICRORNA EXPRESSION; CELL-PROLIFERATION; DRUG-RESISTANCE; TARGETING BCL2; THERAPY; CHEMORESISTANCE; MECHANISM;
D O I
10.1038/cddis.2013.193
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Resistance to fluoropyrimidine-based chemotherapy is the major reason for the failure of advanced colorectal cancer (CRC) treatment. The lack of ability of tumor cells to undergo apoptosis after genotoxic stress is the key contributor to this intrinsic mechanism. Mounting evidence has demonstrated that non-coding microRNAs (miRNAs) are crucial regulators of gene expression, in particular, under acute genotoxic stress. However, there is still limited knowledge about the role of miRNAs in apoptosis. In this study, we discovered a novel mechanism mediated by microRNA-129 (miR-129) to trigger apoptosis by suppressing a key anti-apoptotic protein, B-cell lymphoma 2 (BCL2). Ectopic expression of miR-129 promoted apoptosis, inhibited cell proliferation and caused cell-cycle arrest in CRC cells. The intrinsic apoptotic pathway triggered by miR-129 was activated by cleavage of caspase-9 and caspase-3. The expression of miR-129 was significantly downregulated in CRC tissue specimens compared with the paired normal control samples. More importantly, we demonstrated that miR-129 enhanced the cytotoxic effect of 5-fluorouracil both in vitro and in vivo. These results suggest that miR-129 has a unique potential as a tumor suppressor and a novel candidate for developing miR-129-based therapeutic strategies in CRC.
引用
收藏
页码:e659 / e659
页数:9
相关论文
共 55 条
[1]   Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells [J].
Akao, Yukihiro ;
Noguchi, Shunsuke ;
Iio, Akio ;
Kojima, Keitaro ;
Takagi, Takeshi ;
Naoe, Tomoki .
CANCER LETTERS, 2011, 300 (02) :197-204
[2]   Resistance May Not Be Futile: microRNA Biomarkers for Chemoresistance and Potential Therapeutics [J].
Allen, Kristi E. ;
Weiss, Glen J. .
MOLECULAR CANCER THERAPEUTICS, 2010, 9 (12) :3126-3136
[3]   The functions of animal microRNAs [J].
Ambros, V .
NATURE, 2004, 431 (7006) :350-355
[4]  
[Anonymous], 2007, CompuSyn software for drug combinations and for general dose-effect analysis, and users guide
[5]   Concordant hypermethylation of intergenic microRNA genes in human hepatocellular carcinoma as new diagnostic and prognostic marker [J].
Anwar, Sumadi Lukman ;
Albat, Cord ;
Krech, Till ;
Hasemeier, Britta ;
Schipper, Elisa ;
Schweitzer, Nora ;
Vogel, Arndt ;
Kreipe, Hans ;
Lehmann, Ulrich .
INTERNATIONAL JOURNAL OF CANCER, 2013, 133 (03) :660-670
[6]   Inhibitors of the anti-apoptotic Bcl-2 proteins: a patent review [J].
Bajwa, Naval ;
Liao, Chenzhong ;
Nikolovska-Coleska, Zaneta .
EXPERT OPINION ON THERAPEUTIC PATENTS, 2012, 22 (01) :37-55
[7]   Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues [J].
Bandres, E. ;
Cubedo, E. ;
Agirre, X. ;
Malumbres, R. ;
Zarate, R. ;
Ramirez, N. ;
Abajo, A. ;
Navarro, A. ;
Moreno, I. ;
Monzo, M. ;
Garcia-Foncillas, J. .
MOLECULAR CANCER, 2006, 5 (1)
[8]   Epigenetic regulation of microRNA expression in colorectal cancer [J].
Bandres, Eva ;
Agirre, Xabier ;
Bitarte, Nerea ;
Ramirez, Natalia ;
Zarate, Ruth ;
Roman-Gomez, Jose ;
Prosper, Felipe ;
Garcia-Foncillas, Jesus .
INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (11) :2737-2743
[9]  
Banerjee D, 1998, CANCER RES, V58, P4292
[10]  
Baretton GB, 1996, CANCER, V77, P255, DOI 10.1002/(SICI)1097-0142(19960115)77:2<255::AID-CNCR6>3.0.CO